KDR and neoplasm: By targeting the EGFR-dependent cancer cell proliferation and the VEGFR-2-dependent tumour angiogenesis pathways, vandetanib offers the potential advantages of blocking two key pathways in different tumour types, namely cell proliferation and angiogenesis.